Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (CT03767348) trial in advanced melanoma was not ...

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.

To mark the 10-year anniversary of the drug’s approval, Astra Zeneca launched the first DTC campaign for Tagrisso.

The therapy initiation partner will integrate the service provider’s technology platform to its national network.

The University of California, Berkeley’s incubator for life sciences Bakar Labs announced construction for a new research and development building on campus for early-stage biotech startups.

Previous attempts at treatments have faced many limitations but Amphix Bio is taking a completely new approach to neural regeneration, with the potential for a breakthrough in the field." 1 Amfx-200 ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

The EVERSANA AI Accelerator is our dedicated center of excellence designed to harness the power of artificial intelligence ...

Waterdrop Inc. has been included in Harvard Business school’s (HBS) Case Collection. Inducted as a business innovation case, ...